Image Not Found On Media Library
  • HOME
  • ABOUT MORSE
    • The Team
    • Careers
  • SERVICES
    • Our Services
      • Comprehensive Market Access Launch Strategy
      • Market Access Landscape Analysis
      • HTA Planning and Reimbursement Evidence Strategy
      • Negotiation & Stakeholder Engagement Strategy
      • Portfolio & Life Cycle Strategy
      • Expert-Led Training & Customized Workshops
  • REPORTS
    • NEW – Pre-Order CRaFT 2025
    • 2024 CRaFT Report
    • DRD Market Access Trends & Insights
    • Oncology Market Access Trends & Insights
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
  • LINKS
  • CONTACT US
logo-top-r
Image Not Found On Media Library
  • HOME
  • ABOUT MORSE
    • The Team
    • Careers
  • SERVICES
    • Our Services
      • Comprehensive Market Access Launch Strategy
      • Market Access Landscape Analysis
      • HTA Planning and Reimbursement Evidence Strategy
      • Negotiation & Stakeholder Engagement Strategy
      • Portfolio & Life Cycle Strategy
      • Expert-Led Training & Customized Workshops
  • REPORTS
    • NEW – Pre-Order CRaFT 2025
    • 2024 CRaFT Report
    • DRD Market Access Trends & Insights
    • Oncology Market Access Trends & Insights
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
  • LINKS
  • CONTACT US

CRaFT Mid-Year Update is Here!

September 25, 2024
-
Market Access News, Publications
-
Posted by MORSE - < 1 min read.

We’re excited to announce that the 2024 Canadian Reimbursement & Forecasting Timelines (CRaFT) Mid-Year Update is now available! If you’re subscribed, you can now access the latest insights and data to enhance your market access strategies here:

MORSE Reports Portal

Not a subscriber yet? Don’t miss out—subscribe now to stay informed and take advantage of this valuable resource!

MORSE Subscriptions

Share
Tags
Biosimilars
CADTH
CRaFT
DRD
Forecasting
Market Access
Oncology
Pan Canadian Pharmaceutical Alliance
pCPA
pCPAO
Provincial Funding
Reimbursement
Strategic Planning
← PREVIOUS POST
Accelerating Access: Leveraging Target Zero to Expedite Time to Access for New Therapies
NEXT POST →
Challenges with Integrating Early-Stage Cancer Trial Endpoints into Economic Models: Review of Canadian and International HTA Recommendations

Contact Us

MORSE Consulting Inc.

Toronto | Ottawa, Canada

+1-647-717-3179 (Toronto)

+1-613-864-8645 (Ottawa)

info@morseconsulting.ca

Pre-Order 2025 Report

2025 Canadian Reimbursement and Forecasting Timelines Report

Social
Connect & Follow:
Newsletter – MORSE Signals
Sign up for our free e-mail newsletter service and receive timely and relevant updates related to the emerging developments in the Canadian pharmaceutical reimbursement landscape.

Sign Up
MORSE Consulting Inc. | Deciphering Canadian pharmaceutical market access signals to create reimbursement success.
© 2023 MORSE Consulting Inc. All rights reserved. | Site by Directica Media
CRaFT Mid-Year Update is Here!
Learn More
Learn More